Lung Cancer Clinical Trial

Clinical Trial Finder Lung Cancer Trials

Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

See Locations Near You

Summary

The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC

View Eligibility Criteria

Eligibility Criteria

For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email [email protected]. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.

Inclusion Criteria:

ECOG Performance Status (PS) <=1
Histologically or cytologically confirmed, stage IIIB (malignant pleural effusion), stage IV or recurrent NSCLC
Measurable disease by RECIST guidelines

Exclusion Criteria:

Evidence of predominantly squamous-cell histology
Known CNS metastases
Any prior antineoplastic systemic regimens for NSCLC
Excessive risk of bleeding (including use of therapeutic anticoagulation) and history of thrombotic or embolic cerebrovascular accident
Gross hemoptysis (≥1/2 tsp of red blood)
Uncontrolled hypertension
Clinically significant cardiovascular disease
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
Serious non-healing wound, active peptic ulcer, non-healing bone fracture, or bleeding skin metastasis

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

255

Study ID:

NCT00850577

Recruitment Status:

Terminated

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 55 Locations for this study

See Locations Near You

Acrc/Arizona Clinical Research Center, Inc.
Tucson Arizona, 85715, United States
Sharp Clinical Oncology Research
San Diego California, 92123, United States
Cancer Institute Of Florida
Orlando Florida, 32804, United States
Palm Beach Cancer Institute
West Palm Beach Florida, 33401, United States
Clintell, Inc.
Skokie Illinois, 60077, United States
Cancer Center Of Kansas
Wichita Kansas, 67214, United States
Kentucky Cancer Clinic
Hazard Kentucky, 41701, United States
Annapolis Oncology Center
Annapolis Maryland, 21401, United States
Meritus Center For Clinical Research
Hagerstown Maryland, 21740, United States
North Mississippi Hematology And Oncology Associates, Ltd
Tupelo Mississippi, 38801, United States
Piedmont Hematology Oncology Associates, Pllc
Winston-salem North Carolina, 27103, United States
North Canton Medical Clinic Center
Canton Ohio, 44710, United States
Kaiser Permanente Oncology/Hematology
Portland Oregon, 97227, United States
Guthrie Clinic, Ltd
Sayre Pennsylvania, 18840, United States
Rhode Island Hospital
Providence Rhode Island, 02903, United States
Charleston Hematology Oncology Associates, Pa
Charleston South Carolina, 29414, United States
Cancer Center At Cookeville Regional Medical Center
Cookeville Tennessee, 38501, United States
University Of Tennessee Cancer Institute
Memphis Tennessee, 38104, United States
Blue Ridge Cancer Care
Christiansburg Virginia, 24073, United States
Providence Western Washington Oncology
Lacey Washington, 98503, United States
Local Institution
Fortaleza Ceara, 60336, Brazil
Local Institution
Belo Horizonte Minas Gerais, 30130, Brazil
Local Institution
Porto Alegre Rio Grande Do Sul, 90050, Brazil
Local Institution
Barretos Sao Paulo, 14784, Brazil
Local Institution
Rio De Janeiro , 20231, Brazil
Local Institution
Sao Paulo , 04024, Brazil
Local Institution
Sao Paulo , 05403, Brazil
Local Institution
Marseille Cedex 20 , 13915, France
Local Institution
Paris , 75005, France
Local Institution
Rennes Cedex 9 , 35033, France
Local Institution
Toulouse Cedex 9 , 31059, France
Local Institution
Tours Cedex , 37044, France
Local Institution
Meldola (Fc) , 47014, Italy
Local Institution
Ravenna , 48100, Italy
Local Institution
Rimini , 47900, Italy
Local Institution
Roma , 00189, Italy
Local Institution
Terni , 05100, Italy
Local Institution
Bialystok , 15-54, Poland
Local Institution
Gdansk , 80952, Poland
Local Institution
Otwock , 05-40, Poland
Local Institution
Poznan , 60 56, Poland
Local Institution
Szczecin , 70-89, Poland
Local Institution
Warsaw , 02-78, Poland
Local Institution
Chelyabinsk , 45408, Russian Federation
Local institution
Ivanovo , 15301, Russian Federation
Local Institution
Moscow , 115 4, Russian Federation
Local Institution
Moscow , 11547, Russian Federation
Local Institution
Moscow , 14342, Russian Federation
Local Institution
Port Elizabeth Eastern Cape, 6045, South Africa
Local Institution
Pretoria Gauteng, 0002, South Africa
Local Institution
Cape Town Western Cape, 7570, South Africa
Local Institution
Cape Town Western Cape, 7925, South Africa
Local Institution
Rondebosch Western Cape, 7700, South Africa
Local Institution
Manchester Greater Manchester, M23 9, United Kingdom
Local Institution
Leeds West Yorkshire, LS9 7, United Kingdom
Load More

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

255

Study ID:

NCT00850577

Recruitment Status:

Terminated

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
When Should I Consider Clinical Trials?
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider